Warren Buffett made his money being a 'value investor'.  That means he bought or bought into undervalued companies with great potential.  While I doubt that he would have invested in something as inherently risky as RVX prior to topline, he might well have felt otherwise post-topline and subsequent to full data release.  Even though it is now generally acknowledged that the P3 trial was underpowered, there is considerable positive data that has arguably de-risked the stock to an extent that didn't exist prior to topline.  So what we have now is an undervalued off the radar biotech with significant potential in a diverse and high dollar value market.

There is no question that a healthy degree of financial stability to ensure operational security for the forseeable future would be welcome news for the market.  Ergo, if I had to replace a 75+ year old medical professional board member with a younger savvy partner in a $200M company that is 'striving to become a leading healthcare investment fund that invests in early/mid-stage innovative companies globally' then the choice is, IMO, a no-brainer.......especially at this stage.  Further, this outfit is already in it for $US12M.  If they were to walk away from this now then not only is ORI in the wrong business, but the money that are backing ORI would not be amused.  I don't think that ORI got into this just to make 10% on their $US12M convertible debenture.

The PR a couple of days ago, while highlighting some additional information, did tend to regurgitate data that had already been released, albeit in somewhat of a more 'chest-thumping' way.  Who knows, maybe they are teeing things up for a buyer so that they can look good when they spend however many billions it takes to buy the company.  One can only hope.